Esperion Therapeutis.Inc. sell Northland Securities
Start price
16.03.23
/
50%
€1.91
Target price
16.03.24
-
Performance (%)
4.19%
End price
17.03.24
€1.99
Summary
This prediction ended on 17.03.24 with a price of €1.99. The SELL prediction by Northland_Securities shows the price for Esperion Therapeutis.Inc. slightly increased by 4.19% during the runtime of the prediction. Northland_Securities has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | -17.061% | -17.061% | 59.782% |
| iShares Core DAX® | -6.016% | -4.595% | 1.274% |
| iShares Nasdaq 100 | 0.511% | 0.164% | 14.573% |
| iShares Nikkei 225® | -7.156% | -2.215% | 28.107% |
| iShares S&P 500 | -0.257% | -0.841% | 10.196% |
Comments by Northland_Securities for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at Northland Securities from a "market perform" rating to an "underperform" rating.
Ratings data for ESPR provided by MarketBeat
In the thread Trading Esperion Therapeutis.Inc.
Die von Northland_Securities gewählte maximale Laufzeit wurde überschritten